New capital alongside bond conversions · Biotech
Samplix secures €3m in new capital alongside bond conversions
WLan leads a €25m first closing that includes €22m of existing shareholder debt conversions.
Samplix announced a €25 million first closing on 27 October, comprising €3 million in new capital and €22 million in conversions of existing shareholder convertible bonds. WLanholding GmbH led the financing.
The company will use the financing to expand commercial adoption of its Xdrop single-cell screening platform and build biopharma partnerships. The round remains open with a €30 million target.
Use of funds
Commercial expansion of Xdrop
Expand biopharma and academic partnerships
Develop functional single-cell screening platform
Funding history
New capital alongside bond conversions · This round€3M